智通财经获悉，Oppenheimer将福泰制药公司(VRTX.US)的股票评级从“跑赢大盘”下调为“与市场一致”，此前该公司公布了suzetrigine治疗腰骶神经根病的二期研究结果。该分析师在一份研究报告中告诉投资者，虽然suzetrigine在组内显示出临床意义上的疼痛减轻，但安慰剂组显示出几乎相同程度的减轻，导致两组之间没有明显的区别。
该公司表示，事后分析引起了对稳健性和在后续试验中证明疗效的潜力的担忧，尽管福泰制药计划进入3期项目，等待FDA的讨论。它引用了suzetrigine治疗腰骶神经根病的益处和风险不确定，以及在2025年1月30日(FDA处方药使用费法案日期)之前对其急性支付的商业潜力的怀疑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.